Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00024076
Status:
COMPLETED
Last Update Posted:
2020-08-03
First Post:
2001-09-13
Brief Title:
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Study Overview
Official Title:
Radiofrequency Ablation of Pulmonary Malignancy
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Radiofrequency ablation uses high-frequency electric current to kill tumor cells CT-guided radiofrequency ablation may be effective treatment for lung cancer
PURPOSE Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer
PURPOSE Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer
Detailed Description:
OBJECTIVES
Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies
Determine the efficacy of this treatment in terms of local control in these patients
Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients
OUTLINE Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours
Patients are followed at 1 3 6 and 12 months
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study
Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies
Determine the efficacy of this treatment in terms of local control in these patients
Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients
OUTLINE Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours
Patients are followed at 1 3 6 and 12 months
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G01-2011 | None | None | None |
| UCLA-9908024 | None | None | None |